 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 19 | 19 | | 1997 | 0 | 32 | 32 | | 1998 | 0 | 20 | 20 | | 1999 | 0 | 23 | 23 | | 2000 | 0 | 33 | 33 | | 2001 | 0 | 43 | 43 | | 2002 | 0 | 52 | 52 | | 2003 | 0 | 63 | 63 | | 2004 | 0 | 67 | 67 | | 2005 | 0 | 65 | 65 | | 2006 | 1 | 63 | 64 | | 2007 | 0 | 72 | 72 | | 2008 | 0 | 89 | 89 | | 2009 | 0 | 69 | 69 | | 2010 | 0 | 63 | 63 | | 2011 | 0 | 66 | 66 | | 2012 | 0 | 71 | 71 | | 2013 | 0 | 56 | 56 | | 2014 | 0 | 86 | 86 | | 2015 | 0 | 71 | 71 | | 2016 | 0 | 66 | 66 | | 2017 | 1 | 71 | 72 | | 2018 | 0 | 53 | 53 | | 2019 | 0 | 52 | 52 | | 2020 | 0 | 38 | 38 | | 2021 | 0 | 23 | 23 | | 2022 | 0 | 5 | 5 | | 2023 | 1 | 2 | 3 | | 2024 | 0 | 18 | 18 | | 2025 | 0 | 12 | 12 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Moore CF, Bergeria CL, Sempio C, Klawitter J, Christians U, Weerts EM. High doses of orally administered cannabigerol produce deficits in sustained attention in female rats. Pharmacol Biochem Behav. 2026 Mar; 260:174154.
-
Almond CS, Daly KP, Albers EL, Alejos JC, Ameduri R, Auerbach SR, Barkoff L, Barnes AP, Bock MJ, Butto A, Carlo WF, Castleberry CD, Chrisant MR, Deshpande SR, Dreyer WJ, Everitt MD, Feingold B, Gonzales S, Hollander SA, Kindel SJ, Klein GL, Lal AK, Lamour JM, Lee J, Lu M, Lytrivi ID, Miyamoto SD, Pahl E, Peng DM, Ryan TD, Singh TP, Su JA, Sutcliffe DL, Ybarra AM, Zangwill S, Rossano JW, Sleeper LA. Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Lieu CH, Lenz HJ, Benson AB, Meng X, Kim UI, Kim SH, Kim K, Sung MJ. A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors. Cancer Res Commun. 2025 Oct 01; 5(10):1771-1778.
-
Pillar S, Thomas A, Hassman LM, Chen H, Gangaputra S, Kopplin LJ, Boyd K, Moussa K, Pham DC, Chen K, Jackson NJ, Tsui E. Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis: A Multicenter Study. Ophthalmology. 2026 Feb; 133(2):187-193.
-
Goodman JE, Korchevskiy A, Wylie AG. Comparison of various methodological approaches to model asbestos thresholds for mesothelioma. Front Public Health. 2025; 13:1569343.
-
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24; 392(16):1569-1581.
-
Becker WC, Seal KH, Nelson DB, DeRonne BM, Kats AM, Morasco BJ, Frank JW, Makris UE, Painter JT, Allen KD, Mixon AS, Bohnert A, Reznik TE, Hagedorn HJ, Hammett P, Borsari B, Baxley C, Krebs EE. Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical Trial. JAMA Intern Med. 2025 04 01; 185(4):372-381.
-
Zhou X, Mould DR, Gore L, Bai X, Gupta N. Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis. Clin Pharmacol Ther. 2025 Jun; 117(6):1803-1810.
-
Jutabha P, Kumar V, Anzai N, Rice PJ, Lightner JW, Endou H, Wempe MF. Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies. Drug Des Devel Ther. 2025; 19:1377-1392.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|